These included LAMA3 mutations (lung squamous) and NOS1 mutations (breast cancer), which were identified as MEK inhibitor-specific biomarkers, and ST18 mutations (lung adenocarcinoma and ovarian cancer), which were identified as HDAC inhibitor-specific biomarkers. This evidence concerns the gene MAP2K7 and lung adenocarcinoma.